EDINBURGH, UK, December 2, 2014 – SIRAKOSS, an innovative medical device company based in Edinburgh and Aberdeen today announced it has secured $4.8m (£3.1m) in Series-A financing from a syndicate of investors led by Epidarex Capital. Synthetic bone grafts are used in trauma, spinal and…
CRESTWOOD, KY November 20, 2014 – Apellis Pharmaceuticals Inc. Complement inhibition is the only mechanism thus far to show reductions in the growth of dry AMD. Potentia was the first company to develop a complement inhibitor for the treatment of AMD. APL-2 has the same…
October, 2014 – Epidarex is a specialist life science venture capital group that recently raised a new fund of £47.5 million dedicated to UK start ups and university spin outs. Backers include US drug giant Eli Lilly, the Universities of Edinburgh, Glasgow and Aberdeen, King’s…
Epidarex Capital, a leading international venture capital firm, has raised over £47.5 million to lead investments in early-stage life science and health technology companies, including spin-outs from leading research universities. Global pharmaceutical company Eli Lilly and Company participated in the final closing with a significant…
Bethesda, MD, February 18, 2014 – Epidarex Capital, a leading international early-stage life science venture capital fund, has invested in Confluence Life Sciences Inc., a biotechnology company focused on the rapid discovery and development of drugs to address unmet needs in cancer and chronic inflammatory…
Edinburgh, United Kingdom, February 7, 2014. Epidarex Capital, a leading international early-stage life science venture capital fund, has announced a £4 million Series A investment, in Edinburgh Molecular Imaging (EMI). Scottish Enterprise’s investment arm, the Scottish Investment Bank, also participated in the round. EMI, an…
Louisville, Kentucky – August 21st, 2013 – Rock Spring Ventures has increased its investment in Apellis Pharmaceuticals Inc., an early-stage biotechnology company focused on developing a novel pipeline of anti-inflammatory products through a combination of in-licensing of preclinical compounds and in-house research and development. Apellis…
Edinburgh, United Kingdom – January 21st 2013 – Rock Spring Ventures today launched a unique £50m venture capital fund focusing on early-stage life science and health technology companies. Based in Scotland, the fund will invest in young companies developing novel approaches to unmet needs in…